XPA and skin basal cell carcinoma: a population-based study in New Hampshire with nearly 900 cases of BCC and 700 of SCC, observed by Miller et al [13] indicated a 15–25% decreased risk of either BCC or SCC among those with the XPA A23G (rs1800975) polymorphism.